SCHEMBL4575111

SCHEMBL4575111

C=Cc1ccc(S(=O)(=O)N(CC)CC)cc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
HTT P42858 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
TDP1 Q9NUW8 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM1A O60341 1/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
POLB P06746 1/20 0.48
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
TSHR P16473 1/20 0.47
KAT8 Q9H7Z6 1/20 0.47
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802110 0.85 LMNA (0.68) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL11867695 0.83 SMN1; SMN2 (0.50) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL24791584 0.81 MEN1 (0.53) LMNAHTTSMN1; SMN2NPC1TDP1
SCHEMBL24791588 0.79 TDP1 (0.47) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL4069104 0.79 LMNA (0.70) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1494554 0.79 TDP1 (0.55) LMNAHTTSMN1; SMN2TDP1MEN1
SCHEMBL19389695 0.79 TDP1 (0.55) LMNAHTTSMN1; SMN2TDP1MEN1
SCHEMBL13756091 0.77 GLA (0.63) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL5023540 0.76 HTT (0.73) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL23057256 0.76 LMNA (0.73) LMNAHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307570-A Cyclopropyl borate compound and preparation method thereof 南方科技大学 2024-07-09 CN disclosed
US-9763978-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2017-09-19 US disclosed
CN-101360505-B Pharmaceutical composition comprising a polymeric binder comprising a non-hydrolysable covalent bond and its use in the treatment of celiac disease UNIVERSITE DE MONTREAL (CA) 2015-09-09 CN disclosed
US-20150064131-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2015-03-05 US disclosed
CN-102784165-B Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease VALORISATION RECH LTD PARTNERS 2015-02-25 CN disclosed
US-8883133-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable their use in treating celiac disease VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2014-11-11 US disclosed
US-8784792-B2 Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease Valorization-Recherche Limited Partnership (CA) 2014-07-22 US disclosed
CN-102784165-A Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease VALORISATION RECH LTD PARTNERS 2012-11-21 CN disclosed
US-20120244105-A1 Pharmaceutical Compositions Comprising Polymeric Binders with Non-Hydrolysable Covalent Bonds and Their Use in Treating Celiac Disease VALORISATION-RECHERCHE LIMITED PARTNERSHIP (CA) 2012-09-27 US disclosed
CN-101360505-A Pharmaceutical composition comprising a polymeric binder comprising a non-hydrolysable covalent bond and its use in the treatment of celiac disease VALORISATION RECH LTD PARTNERS (CA) 2009-02-04 CN disclosed
US-20080254099-A1 Such as high molecular weight copolymer of hydroxyethyl methacrylate and 4-styrene sulfonic acid sodium salt; decreasing interaction of gluten or peptide degradation products with intestinal tract; breads VALORISATION-RECHERCHE, LIMITED (CA) 2008-10-16 US disclosed
EP-1948201-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE UNIVERSITE DE MONTREAL (CA) 2008-07-30 EP disclosed
WO-2007053935-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMERIC BINDERS WITH NON-HYDROLYSABLE COVALENT BONDS AND THEIR USE IN TREATING CELIAC DISEASE UNIVERSITE DE MONTREAL (CA) 2007-05-18 WO disclosed